Advanced Therapies Commercialization

 

Advanced Therapies - Commercialization, Monday 24 August 2020

09:50

BREAK

Ellen Coleman
10:05

Chairperson’s opening remarks

Ellen Coleman, President And Chief Executive Officer, VOZ Advisors
Jeremy Levin
10:10

Keynote Address: Rare diseases in the time of Covid-19

Jeremy Levin, Chairman and Chief Executive Officer, Chairman, BIO, Ovid Therapeutics
Emil Kakkis
10:35

Keynote Address: The future of rare diseases: developing and accessing the next generation of therapies

Emil Kakkis, Chief Executive Officer, Ultragenyx Pharmaceutical
Neena Nizar
10:55

Keynote Panel: Patient involvement in drug development for rare diseases – examining how patients are driving meaningful development and what companies are doing to incorporate patient input throughou

Neena Nizar, President, The Jansens Foundation
Dara Richardson-Heron, Chief Patient Officer, Pfizer
Yann Le Cam, Chief Executive Officer, EURORDIS
11:45

EXHIBITOR HALL BREAK

13:50

BREAK

15:10

BREAK

Oodaye Shukla
17:10

Keynote Panel: Examining industry strategies for leveraging patient data and AI to advance rare disease patient identification, R&D, and commercialization

Moderator: Oodaye Shukla, Chief Data Officer, HVH Precision Analytics
Pamela Gavin, Chief Strategy Officer, National Organization for Rare Disorders (NORD)
Sonalee Agarwal, Vice President Of Value And Evidence Strategy, Alnylam Pharmaceuticals
Sean Khozin, Global Head Of Data Strategy, Johnson & Johnson
Thomas Abbott, Head, Real World Data And Evidence, Astellas Pharma
last published: 16/Jul/20 14:15

 

Advanced Therapies - Commercialization, Monday 24 August 2020

last published: 16/Jul/20 14:15